PTC Therapeutics

NAS:PTCT

Biotechnology

Market Cap

$1.92bn

SMALL cap

Share Price ↑

$32.94 (5.00%)

YTD Return ↓

-1.9935%

since start of 2019

P/E Ratio

—

PTCT chart by TradingView

Source: FactSet financial data and analytics.

Corporate Values

Carbon Footprint
Pollution Prevention
Water Conservation
Data Privacy
Consumer Health
Employee Satisfaction
Workplace Safety
Corp Gov
Ethical Practices
Conflict Materials
Forced Labor
Gender Diversity

Legend

About

Biotechnology Founded 1998

PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel medicines using its expertise in RNA biology. The company's internally discovered pipeline addresses multiple therapeutic areas, including rare disorders and oncology. It is focused on developing treatments to fundamentally change the lives of patients living with rare genetic disorders. The company was founded by Allan S. Jacobson and Stuart W. Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.

website

Source: FactSet Research Systems

Headquarters

100 Corporate Court

South Plainfield, NJ 07080-2449

1.908.222.7000

Executives

Name	Title	Gender
Michael Schmertzler, MBA	Chairman	Male
Stuart W. Peltz, PhD	Chief Executive Officer & Class I Director	Male
Mark Elliott Boulding	Secretary, Chief Legal Officer & Executive VP	Male
Allan Steven Jacobson, PhD	Independent Class III Director	Male
Martin Rexroad	Senior Vice President-Human Resources	Male
Jane Baj	Head-Investor Relations	Female
Neil Gregory Almstead, PhD	Executive VP-Research, Operations & Technology	Male
Shane William Charles Kovacs, CFA, MBA	CFO & Head-Corporate Development	Male
Tuyen Ong, MD, MBA	Chief Medical Officer	null

Mindful Investing Summary

Legend

Carbon Footprint — N/A

PTC Therapeutics among its competitors for its carbon footprint. A company’s performance in this category is based on its success in implementing energy efficiency measures. Investments in energy efficient technology, green building and sourcing of renewable energy can all lead to cost savings and reduce the company’s contribution to climate change.
Pollution Prevention — N/A

PTC Therapeutics on this issue. Companies are evaluated on pollution prevention by the levels of waste (including hazardous waste) they produce and release into the environment, and can be affected by whether they develop products that can reduce exposure to pollution.
Water Conservation — N/A

PTC Therapeutics among its peers in this category. A company’s score in this category depends on its measures to minimize water usage and impacts on stressed or drought-prone water resources.
Data & Privacy Protection — N/A

PTC Therapeutics among its peers and competitors for data privacy and protection. Companies today digitally manage vast amounts of personal information about their clients. A company’s score on this issue is based on the systems, products and procedures it has in place to minimize the risk for data and privacy breaches.
Consumer Health, Wellness & Safety — N/A

PTC Therapeutics compared to its peers and competitors Companies in this category manage its product and safety risks.
Employee Ownership, Satisfaction, Benefits & Pay — N/A

PTC Therapeutics among its peers for employee satisfaction and pay. A company’s score on this issue depends on its frequency and likelihood of labor disputes as well as its practices to keep and retain talent - such as compensation, family leave, employee health care and other benefits. Employers that are rated as good to work for consistently produce higher stock returns than their peers.
Workplace Health and Safety — N/A

PTC Therapeutics among its competitors on this issue. A company’s workplace health and safety is evaluated not only by the number of accidents and injuries in the workplace, but also by their safety policies, training procedures, and their investment in equipment that can reduce accidents.
Integrity of Corporate Governance — N/A

PTC Therapeutics among its competitors on corporate governance. This score is determined by the company’s accounting practices, executive pay, board organization and ownership structure.
Ethical Practices — N/A

PTC Therapeutics compared to its peers and competitors. A company’s rating on this issue is based on its history of controversies related to unethical corporate behavior, such as false claims about their products, price fixing, executive misconduct, insider trading or fraudulent practices.
Usage of Conflict Materials — N/A

PTC Therapeutics among its competitors in this category. Certain products use raw materials that are commonly sourced from militias or other organizations that promote or engage in conflict in their region. To perform well in this category companies must provide adequate assurances that any of these metals used in their production are in fact from conflict-free sources.
Forced Labor — N/A

PTC Therapeutics compared to its competitors on forced labor. A company’s score on this issue depends on its use of forced labor and on its work conditions for outsourced labor.
Diversity of Corporate Leadership 2 N/A

PTC Therapeutics performs poorly based on its peers as well as companies in similar geographic regions. Companies are assessed on factors such as board diversity and senior management diversity. Companies performing well on this issue typically are more profitable than its peers, while companies with very poor scores typically have greater stock price volatility and lower returns on capital.

PTC Therapeutics - Competitors and Related Companies

How PTC Therapeutics stacks up to its peers in the Biotechnology industry or with competing business segments.